• AAPL 165
  • TSLA 147.05
  • AMZN 174.63
  • MSFT 399.12
  • INTC 34.2
  • EURUSD 1.0661
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. AFMD.NASDAQ

Affimed NV (AFMD NASDAQ) stock market data APIs

$5.13 -0.02(-0.4%) as of April 19, 2024

Affimed NV Financial Data Overview

5.15
5.13
-
5.21
5
2.235-11.1
78 422 K
15 228 K
13 914 K
-1.35
2.091
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'AFMD',
Type: 'Common Stock',
Name: 'Affimed NV',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG006R5SSH5',
ISIN: 'NL0010872420',
CUSIP: 'N01045108',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: '2014-09-12',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

Affimed NV Fundamental Data is available in our Financial Data APIs

  • Net Revenue 13 914 K
  • EBITDA -102 586 000
  • Earnings Per Share -7.56
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Affimed NV Earnings via APIs

  • Latest Release 2024-03-28
  • EPS/Forecast -1.54

Get Affimed NV End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Affimed NV latest news via APIs

Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer

Affimed N.V. Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer (NSCLC) expansion cohort Follow-up...

Affimed Announces Leadership Change and Organizational Restructuring

Affimed N.V. Dr. Adi Hoess to step down as CEO and Management Board Member Dr. Andreas Harstrick appointed Interim CEO Strategic restructuring reducing headcount by up to 50%, extending cash runway i...
Do you have any questions?
support@eodhistoricaldata.com